Effect of new beta-adrenergic blocking agent, Atenolol (Tenormin), on pain frequency, trinitrin consumption, and exercise ability.
- 26 July 1975
- Vol. 3 (5977), 195-197
- https://doi.org/10.1136/bmj.3.5977.195
Abstract
In 11 patients with severe angina pectoris a new beta-blocking drug, atenolol (Tenormin; I.C.I.66082), was found in a double-blind randomized trial to reduce significantly the frequency of anginal attacks (P less than 0-001) and the amount of trinitrin consumed (P less than 0-03) in comparison with practolol and placebo. There was no significant improvement in the patients' ability to exercise on the bicycle ergometer.Keywords
This publication has 6 references indexed in Scilit:
- Effect of a new beta-adrenergic blocking agent, ICI 66o82, on exercise haemodynamics and airway resistance in angina pectoris.Heart, 1974
- Trasicor (39,089/Ba) in angina pectoris. A single-blind trial.1968
- Propranolol in the therapy of angina pectorisThe American Journal of Cardiology, 1966
- Cardiac output after beta-adrenergic blockade in ischaemic heart disease.Heart, 1965
- Double-blind Trail to Propranolol (Inderal) in Angina PectorisBMJ, 1965
- EFFECT OF A β-ADRENERGIC-BLOCKING AGENT, PROPRANOLOL, ON ASTHMATICSThe Lancet, 1964